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A B S T R A C T
Purpose: To evaluate the psychometric properties of the Serbian-language version of the Quality of Life in
Epilepsy Inventory-31 (QOLIE-31).
Methods: After undergoing a translation and cultural adaptation of its items in order to create a Serbian-
language version of QOLIE-31, we assessed its psychometric properties—reliability, construct validity
and criterion validity. The sample consisted of 203 adults with epilepsy. Reliability was tested both by
assessing the internal consistency and by the test‘retest method. Construct validity was assessed by
factor analysis, multitrait-scaling analysis and method of known-groups validation. This was achieved
by assessing the relationship between scales and external measures (socio-demographic characteristics,
seizure severity and etiology of epilepsy). Criterion validitywas assessed by correlation analysis between
QOLIE-31 and Short form 36 health survey (SF-36) and Neurotoxicity scale-II.
Results: The domains showed high internal consistency (Cronbach’s a 0.94). Test–retest reliability for
Overall test score was 0.83 (Pearson’s coefﬁcient) indicating temporal stability. Seizure severity and
etiology of epilepsy signiﬁcantly inﬂuenced all QOLIE-31 domains except the Medication effect domain,
with lowest scores in high seizure severity and symptomatic etiology groups. Employment status
signiﬁcantly inﬂuenced Overall quality of life, Emotional well-being, Social function and Overall score.
Educational level was related to the Emotional well-being domain, with highest scores for students. The
QOLIE-31 was highly positively correlated with SF-36 (rho = 0.898) and strongly negatively correlated
with Neurotoxicity scale-II (rho = 0.783).
Conclusion: Serbian adaptation of the QOLIE-31 questionnaire is reliable and valid for assessing the
quality of life in patients with epilepsy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Over the past three decades research into quality of life (QOL)
has become increasingly prominent. It has allowed for assessment
of the overall impact of diseases and medical treatments on an
individual’s life from the patient’s point of view. The rationale of
QOL research was that tracking health-related quality of life
(HRQOL) in different populations can identify subgroups with poor
physical or mental health, which are often associated with chronic§ The work was carried out at the Department for Epilepsy and Clinical
Neurophysiology, Institute of Mental Health, Palmotic´eva 37, Belgrade.
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doi:10.1016/j.seizure.2010.07.012diseases, and can help guide policies or interventions to improve
the health status.1,2 The HRQOL research developed two main
types of instruments: (1) Generic scales, used for comparisons of
health status between different diseases and applicable to virtually
all people, and (2) Disease-speciﬁc scales, used to assess health
status in individuals with particular diseases or conditions.2 One of
the most widely used generic QOL scales is Short Form Health
Survey (SF-36).3
Epilepsy is a chronic disease. It adversely affects both physical
and psychosocial functioning inmanifoldways evenwhen seizures
are controlled. The need to better understand and measure the
distress of people with epilepsy (PWE) stimulated the develop-
ment of many HRQOL scales. As recently stated, QOL studies in
epilepsy should preferably employ scales with known psychomet-
ric properties (reliability, validity and responsiveness), widespread
in use (used by more than one author, and used in more than ﬁve
studies) and speciﬁc to epilepsy, assessing at least side effects ofvier Ltd. All rights reserved.
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scales include: (1) Quality of Life in Epilepsy Inventory-89 items
(QOLIE-89)5; (2) Quality of Life in Epilepsy Inventory-31 items (the
shortened form of the QOLIE-89, known as QOLIE-31)6; (3) Quality
of Life in Epilepsy Inventory-10 items (QOLIE-10) which is used for
screening purposes7; (4) Washington Psychosocial Seizure Inven-
tory (WPSI)8; (5) Epilepsy Surgery Inventory (ESI-55), whose
purpose is pre-surgical evaluation9; and (6) Liverpool Health
Related Quality of Life Battery (Liverpool HRQOL).10
The QOLIE-31 was originally created in the United States of
America (USA) as the shortened form of the QOLIE-89. It was
designed to serve as an epilepsy-speciﬁc instrument for rapid
evaluation of the major HRQOL domains that are of concern to
adults with epilepsy.6 The psychometric properties of the original
USA version have been assessed in detail,6 and the QOLIE-31 has
been demonstrated to be a responsive measure with respect to
seizure frequency and self-reported overall condition.11 The
instrument has been and is currently used in numerous clinical
studies,12–15 becoming one of the most frequently used epilepsy-
speciﬁc HRQOL scales.
Since QOLIE-31 was initially developed for use in the context of
USA culture, translation and cultural adaptation are necessary in
order to make it usable for assessing QOL in other cultures. Recent
studies evaluated the psychometric properties of the QOLIE-31 in
several different linguistic and cultural groups, using among others
Spanish, German, French, Italian, Greek, Portuguese and Czech-
language versions of QOLIE-31.16–22
Speciﬁc psychometric data are lacking for the Serbian-language
version of the QOLIE-31. In this paper, we report the data from a
validation study on the translated and culturally adapted Serbian
version of QOLIE-31.23
2. Method
2.1. Cross-cultural translation
One of the authors (ZM) obtained the permission to translate
QOLIE-31 into Serbian from the QOLIE Development Group (J.
Cramer). The original English version of the QOLIE-31 was
translated into Serbian by a bilingual translator independent of
the study itself. This ﬁrst Serbian version was subsequently back-
translated and differences from original wording in the USA
versionwere discussed by a panel of experts including neurologists
and English and Serbian language teachers. They used content
correspondence as the main guideline when agreeing on ﬁnal item
wording. The layout and the images of the Serbian version were
identical to the original instrument. The ﬁnal version was tested in
a pilot study that included 30 adult PWE, which conﬁrmed a high
level of item acceptance and comprehension. This preliminary
study conﬁrmed that the Serbian-language version was equivalent
in content and meaning to the original American version.
2.2. Study population
All adult PWE who consecutively attended regular appoint-
ments at the Department of Epilepsy and Clinical Neurophysiology
of The Institute of Mental Health in Belgrade were recruited for
participation in the study. PWE aged 18–65 years with a proven
diagnosis either of partial epilepsy or of primarily generalized
epilepsy24,25 and good compliance with antiepileptic drugs were
eligible if they were able to understand and complete the
questionnaires. PWE gave informed consent prior to participating
in the study. Exclusion criteria were: presence of a signiﬁcant
psychiatric disorder, progressive neurological disease, and con-
comitant use of neuroleptic drugs, cranial trauma or craniotomyduring the last year. Study was approved by the Ethical Committee
of the Medical School at the University of Belgrade.
2.3. Questionnaires
We applied three scales: (1) the Serbian translation of the
QOLIE-31 used in the original report by Cramer et al.,6 (2) the SF-
363 and (3) the Neurotoxicity scale-II.26 The latter two scales were
used to assess the criterion validity of the Serbian-language
version of QOLIE-31. Socio-demographic data were obtained using
a semi-structured interview. Clinical characteristics of epilepsy
were obtained from the medical records of patients.
The original QOLIE-316 includes 30 items clustered in seven
multi-item scales and one single item (item 31) on overall health.
Multi-item scales are centered on the following domains: Seizure
worry (SW: items 11, 21–23, 25); Overall quality of life (OQL: items
1, 14); Emotional well-being (EWB: items 3–5, 7, 9); Energy/
Fatigue (EF: items 2, 6, 8, 10); Cognitive functioning (COG: items
12, 15–18, 26); Medication effects (ME: items 24, 29, 30); Social
functioning (SF: items 13, 19, 20, 27, 28). A scoring system is
available for each item (raw score from 0 to 3 or from 0 to 6) and is
calculated for each scale. The raw values were converted to 0–100
scores, with higher values reﬂecting better quality of life (from 0,
the worst HRQOL, to 100, the best). The scores are calculated for
each domain and the overall score is obtained by using a weighted
average of the multi-item scale scores.27
SF-36 is the most widely evaluated tool for measuring patient-
reported outcomes. As documented in several thousand publica-
tions, this generic health survey can be used across age, disease and
treatment group and is appropriate for a wide variety of
applications. It yields an 8-domain proﬁle including: Bodily pain,
General health, Mental health, Physical functioning, Role emotion-
al, Role physical, Social functioning and Vitality. All questions are
scored on a scale from 0 to 100, with 100 representing the highest
level of functioning possible. Aggregate scores are compiled as a
percentage of the total points possible, using the RAND scoring
table SF-36.3,28 We applied version 2 (SF-36v2)—Serbian-language
translation.3 Scoring and calculation of scales were performed by
using the Ware’s survey manual.28
Neurotoxicity scale-II (NTS-II) was devised as a patient-based
report scale to assess the adverse effects of antiepileptic drugs on
cognitive function.26 The scale is comprised of six cognitive
domains: fatigue, slowing, memory, concentration, motor coordi-
nation and language. The most valid primary outcome measure is
the overall score (from 0 to 72) that renders a global (‘all or
nothing’) evaluation indicating whether a subject experiences
cognitive impairment and associates this with the antiepileptic
drug treatment. Its validation suggested the maximal applicability
as a screening instrument in outpatient practice and in phase II and
IIIa drug trials.
2.4. Methods for discriminative power, reliability and validity
assessment
Discriminative power was assessed by checking deviations of
scores from the normal distribution for the whole scale and for the
subscales on QOLIE-31. Deviations were tested by Kolmogorov–
Smirnov test and by coefﬁcients of distortion (Skewness and
Kurtosis).
Assessment of reliability involved the calculations of internal
reliability and Test–retest reliability (repeatability).29–31 Internal
consistency was assessed with Cronbach’s a coefﬁcient. Conven-
tionally, a value above 0.70 is regarded as acceptable, values above
0.8 are considered good, and values above 0.9 are thought to be an
excellent indicator of internal consistency.29 Repeatability was
evaluated by retest measurement after a period of 2–3 weeks from
Table 1
Socio-demographic characteristics of patients.
Number of patients %
Sex
Male 85 41.9
Female 118 58.1
Age
Mean: 37.9313.64 years
Range: 18–65 years
Residence
Belgrade 126 62.1
Other town 55 27.1
Rural 22 10.8
Level of education
8 years 47 23.2
11–13 years 110 54.2
Faculty 46 22.6
Employment status
Students 24 11.8
Employed 97 47.8
Unemployed 51 25.1
Retired 31 15.3
Marital status
Single 102 50.2
Married 85 41.9
Divorced 10 4.9
Widowed 6 3.0
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not undergo any changes between the ﬁrst and the second
assessment.
Construct validity of QOLIE-31 was assessed by exploratory
factor analysis using a method of principal component analysis
with orthogonal varimax rotation. Plausible factors were extracted
using the Guttmann–Kaiser Criterion or Kattel’s scatter diagram.
Additionally, we used multitrait-scaling analysis for assessing
construct validity.29–31 Item-scale correlations were assessed by
Pearson’s correlation coefﬁcients, considering the level of at least
0.4 as an acceptable correlation coefﬁcient. Lastly, for assessing the
construct validity of the QOLIE-31 questionnaire we also used the
method of known-groups validation. We hypothesized that: (1)
QOLIE-31 scores should be lower (i.e., worse QOL) in PWE with a
higher seizure severity (a composite measure based on seizure
frequency and seizure types),32,33 (2) QOLIE-31 scores should be
signiﬁcantly higher (i.e., better QOL) in PWE with idiopathic
epilepsy than in PWE belonging to cryptogenic or symptomatic
epilepsy subgroups, and (3) that differences in educational and
employment status will signiﬁcantly affect QOLIE-31 scores. These
hypotheses were tested using the analysis of variance (ANOVA).
To assess criterion validity we determined the correlations of
instrument scores with external measures on other similar
instruments (SF-36 and Neurotoxicity scale-II). The relationship
between scales of QOLIE-31 and SF-36 was tested using Pearson’s
correlation coefﬁcients and canonical correlation analysis. Strong
correlations were expected between domains and scales with the
same content, for example between the overall scores of the
QOLIE-31 Serbian-language version and SF-36. In addition, a strong
negative correlation was expected between QOLIE-31 and
Neurotoxicity scale-II.
As a criterion for rejecting the null hypothesis we used a level of
signiﬁcance of 5% (p < 0.05). For psychometric and statistical
analysis we used SPSS for Windows (Version 12.0, SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Socio-demographic sample characteristics
The sample consisted of 203 patients, 118 women (58.1%) and
85 men (41.9%) with a mean age of 37.93 years (SD  13.64; range
18–65). Around half of patients (N = 110, 54.18%) were re-tested after
a 2–3 weeks interval. The socio-demographic characteristics are
shown in Table 1 and clinical characteristics in Table 2.
3.2. Descriptive statistics and discriminative power
Missing items. For each item there were missing items, mostly
this ranged from a minimum of 1 to a maximum of 6, 1.3% on
average. In the domain Social function, item 20 (driving) was
missing in 55 (27.1%) and item 27 (work limitations) in 7 (3.4%).
After the exclusion of the item ‘‘driving’’ the number of fully
answered questionnaires increased to 96.4%. According to the
Scoring Manual,27 missing values can be overcome by calculating
scale scores in a different way: the total sum of valid item scores is
divided by the number of items with valid responses in the scale.
Summary of descriptive statistics of QOLIE-31 scores are
presented in Table 3. Mean overall score was 70.64  17.74.
Discriminative power testing showed that domains Seizure worry
and Overall quality of life showed an almost normal distribution
while the remaining scales showed positive skewness, i.e., distribu-
tion with an asymmetric tail extending toward more positive values.
This is particularly true for Emotional well-being, Energy/Fatigue,
Cognitive, Medication effects and Social function (Table 4).3.3. Reliability
Internal consistency. As depicted in Table 3, calculation of
Cronbach’s a demonstrated a good internal consistency of the
overall scale (0.94) and of all of its speciﬁc dimensions, especially
for Emotional well-being (0.86). On the other hand, internal
consistency was lower although still acceptable for Overall quality
of life—0.72 (only two items), and for Social function—0.75 (item
20–27.1% missing).
Repeatability. Test–retest demonstrated that QOLIE-31 was
reliable since Pearson’s correlation values were moderately highly
or highly signiﬁcant for each domain score, ranging from 0.606 to
0.797, and 0.829 for the overall score (Table 3).
3.4. Validity
Construct validity. Factor analysis on 30 items led to the
extraction of 6 factors with eigenvalues >1, according to
Guttmann–Kaiser Criteria (Table 5). Katel’s scatter diagram
indicated that a single factor could be extracted with high loadings
on all items. After varimax matrix rotation six factors were
extracted. Second factor corresponds to the Cognitive domain (5/
6 items) and third factor to Seizure worry (5/5) domain of the
original questionnaire. First factor was more heterogeneous,
containing high loadings from all items from the Emotional well-
being domain, all items from the Energy/Fatigue domain and the
Overall qualityof life domain. Fourth factor included two items from
Social functionand two fromMedicationeffectsdomains,ﬁfth factor
had one item from Social function and one from Cognitive domains.
Sixth factor contained a single item from Social function: item 20
(driving) which had a high rate of missing values (see Appendix A).
Thus, exploratory factor analysis did not extract solutions that
matched those obtained from originally designed domains
Since previous research had shown some stability of proposed
scales in non-English versions we used multitrait-scaling analysis
as an additional method to check construct validity. Item-scale
correlations were calculated for the 30 items that form the seven
original domains (Appendix B). In every instance, individual items
correlated more signiﬁcantly with the domain on which that item
loaded than with other domains. Item-scale correlations were
uniformly very high for all domains, including: Seizure worry
Table 5
The factor analysis—six factors extracted with principle-component analysis.
Factors Eigen values non-rotated Eigen values rotated
Total % Variance Total % Variance
1 11.813 39.378 5.399 17.996
2 3.203 10.678 3.899 12.995
3 1.794 5.982 3.785 12.618
4 1.350 4.500 3.460 11.533
5 1.147 3.824 2.383 7.945
6 1.061 3.538 1.444 4.812
Table 2
Clinical characteristics of epilepsy.
Number of
patients
(n=203)
%
Age of onset
Mean: 19.411.5 years
Range: 0–60 years
Duration
Mean: 18.612.9 years
Range: 1–60 years
Etiology
Idiopathic 61 30
Symptomatic 109 53.7
Cryptogenic 33 16.3
Seizure type
Absence 10 4.9
Myoclonic 25 12.3
Primarily generalized tonic–clonic 52 25.6
Simple partial 72 35.5
Complex partial 109 53.7
Secondarily generalized tonic–clonic 121 59.6
Seizure severity
Controlled (no seizures in past year) 77 37.9
Low (1 gtcs/1–4 cps/1–20
sps/1–20 abs, myo)
53 26.1
Moderate (2–4 gtcs/5–12 cps/21–100
sps/21–100 abs, myo)
33 16.3
High (5–12 gtcs/13–24 cps/101–200
sps/101–200 abs, myo)
40 19.7
Number of AED
Therapy withdrawn 8 3.9
Monotherapy 90 44.3
Polytherapy 105 51.8
gtcs: generalized tonic–clonic seizures; cps: complex partial seizures; sps: simple
partial seizures; abs: absence seizures; myo: myoclonic seizures; AED: antiepileptic
drugs.
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tional well-being (r = 0.746–0.845), Energy/Fatigue (r = 0.781–
0.833), Cognitive functioning (r = 0.599–0.838), Medication effects
(r = 0.746–0.911), and Social function (r = 0.536–0.823).Table 3
Serbian QOLIE-31: summary statistics.
QOLIE domains No. of
items
Mean
(0–100
range)
SD Cronbach’s a Test–retest
correlationsa
(n=110)
Seizure worry 5 65.32 26.31 0.83 0.797
Overall quality of life 2 63.97 18.65 0.72 0.728
Emotional well-being 5 68.48 21.51 0.86 0.726
Energy/Fatigue 4 64.66 21.47 0.82 0.660
Cognitive 6 73.18 22.26 0.81 0.786
Medication effects 3 69.94 28.29 0.80 0.606
Social function 5 78.90 22.48 0.75 0.705
Overall score 30 70.64 17.74 0.94 0.829
a Pearson’s correlation coefﬁcients.
Table 4
Discriminative power.
Skewness Kurtosis Kolmogorov–
Smirnov
df p
Seizure worry 0.65 0.20 0.094 203 0.000
Overall QOL 0.52 0.70 0.086 203 0.000
Emotional well-being 1.03 0.70 0.132 203 0.000
Energy fatigue 0.95 0.50 0.132 203 0.000
Cognitive 0.95 0.51 0.114 203 0.000
Medication effects 0.87 0.17 0.151 203 0.000
Social function 1.00 0.24 0.174 203 0.000
Overall score 0.99 0.81 0.094 203 0.000Differences between seizure severity groups of patients are
demonstrated in overall score as well as in six of the QOLIE-31
domains: Seizure worry, Overall quality of life, Emotional well-
being, Energy/Fatigue, Cognitive, and Social function (Table 6).
The only domain that did not show differences was Medication
effects. Using Scheffe post hoc tests, we showed that only two
extreme groups differed on the six domains. The lowest scores
were found in PWE from the high seizure severity group (mean
OS 58.06), and highest scores in PWE with controlled seizures
(mean OS 72.50). Differences between PWE with idiopathic,
cryptogenic or symptomatic etiology were again evident in six
QOLIE-31 domains: Seizure worry, Overall quality of life,
Emotional well-being, Energy/Fatigue, Cognitive, Social function
and on overall scale score, except in Medication effects subscale
(Table 6). Scores were highest in PWE with idiopathic epilepsy
(mean OS 76.93) and lowest in those with symptomatic epilepsy
(mean OS 67.62). Different employment status was associated
with signiﬁcant differences in Overall quality of life domain,
Emotional well-being, Social function and in Overall score (Table
6). Scheffe post hoc tests differentiated two subgroups with
extreme scores. The highest one comprised students (mean OS
78.68), and the lowest one retired PWE (mean OS 61.59).
Different educational levels affected only the Emotional well-
being domain with lowest scores in PWE with an elementary
school diploma (mean overall score 64.27) and highest scores in
students (mean OS 78.17) (Table 6).
Criterion validity. Pearson’s correlation coefﬁcients between
QOLIE-31 and SF-36 subscales (Table 7) were signiﬁcant and high
for all domains, except for QOLIE-31 Seizure worry and Medica-
tion effects (r < 0.4). This ﬁnding could suggest some speciﬁcity of
these domains. Canonic correlation analysis between QOLIE-31
and SF-36 revealed two signiﬁcant canonical functions. Function
1: high positive canonical correlation (rho = 0.898, x2 = 423.7,
df = 56, p < 0.001) between the two instruments including all
their domains. The highest contributors were SF – Mental health
andVitality andQOLIE-31–Overall quality of life, Emotionalwell-
being, Energy/Fatigue and Cognitive domains. This analysis also
showed lowest correlations between QOLIE-31 Seizure worry and
Medication effects and all SF-36 domains. Function 2 demon-
strated that Energy/Fatigue from QOLIE-31 and Vitality from SF-
36 were highly associated (rho = 0.546, x2 = 108.68, df = 42,
p < 0.001)
Pearson’s correlation coefﬁcient between QOLIE-31 overall
score and NTS-II overall score was highly negative and signiﬁcant
(r = 0.730, p < 0.001). Canonical correlation analysis between
domains showed two signiﬁcant canonical functions. Function
1: high negative correlations between all domains of QOLIE-31
and NTS-II (rho = 0.783, x2 = 243.8, df = 42, p < 0.001); Func-
tion 2: negatively correlated QOLIE-31 Energy/Fatigue and NTS-
II Fatigue (rho = 0.391, x2 = 60.66, df = 30, p < 0.001). This
correlation is negative since a higher QOLIE-31 score signiﬁes
less pronounced fatigue and vice versa.
Table 6
Differences between QOLIE-31 domains depending on external variables.
QOLIE domains (mean score)
SW OQL EWB EF COG ME SF OS
Seizure severity group
Controlled 74.70 64.64 70.51 64.71 73.52 70.07 81.80 72.50
Low 63.72 67.44 72.61 66.79 75.58 68.77 80.55 72.83
Moderate 60.36 61.94 68.59 67.65 73.94 74.28 78.74 70.63
High 52.58 53.42 52.06 50.96 60.96 66.01 66.70 58.06
F 4.830 4.017 7.782 4.955 3.576 0.478 3.838 6.660
p <0.005 <0.01 <0.001 <0.005 <0.05 >0.05 =0.01 <0.001
Etiology of epilepsy
Idiopathic 72.23 69.30 75.38 71.15 79.86 72.31 85.09 76.93
Probably symptomatic 64.99 66.36 69.86 62.98 73.27 62.45 78.80 70.73
Symptomatic 62.13 60.55 64.54 61.93 70.06 71.53 76.16 67.62
F 3.021 4.806 5.293 3.921 4.099 1.574 3.346 5.95
p =0.05 <0.01 <0.01 <0.05 <0.05 >0.05 <0.05 <0.001
Education level
8 years 64.74 59.81 58.82 60.83 62.76 72.13 73.75 64.27
11–13 years 60.88 63.78 68.55 65.68 72.40 67.15 77.94 69.89
Faculty 74.79 63.29 68.23 59.17 77.01 72.22 80.72 72.09
F 1.601 1.525 2.326 0.815 1.896 1.389 0.085 1.62
p >0.05 >0.05 <0.05 >0.05 >0.05 >0.05 >0.05 >0.05
Employment status
Actually students 74.93 73.44 77.29 71.04 80.61 80.56 86.22 78.68
Employed 61.97 64.79 70.73 65.21 74.32 68.98 80.47 71.50
Unemployed 69.79 64.31 67.26 64.87 72.35 70.20 79.12 70.72
In retirement 61.02 53.47 56.61 57.69 65.23 64.24 67.94 61.59
F 2.404 5.790 5.205 1.841 2.365 1.598 3.597 4.65
p >0.05 =0.001 <0.005 >0.05 >0.05 >0.05 <0.05 <0.01
SW: Seizure worry; OQL: Overall quality of life; EWB: Emotional well-being; E/F: Energy/Fatigue; COG: Cognitive; ME: Medication effects; SF: Social function; OS: Overall
score; F: one-way ANOVA. Signiﬁcant values (p<0.05): bold-italic; Non-signiﬁcant values (p>0.05): italic.
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4.1. Reliability of Serbian version
The Serbian QOLIE-31 is interdependent and homogenous in
terms of the concepts it measures, as indicated by the high
Cronbach’s a coefﬁcients (0.94 for overall score), comparable with
original US version (0.93 for overall score),6 as well as with Spanish
(0.92),16 Italian (0.88),19 and Greek version (0.92),20 and much
higher than 0.68 in Czech study22where itwas yet considered to be
acceptable.
The internal consistency was lower for Overall quality of life
(0.72) than for other domains as it contained only two items.
Cronbach’sa is dependent on both themagnitude of the inter-item
correlations and on the number of items contained in the scale.29 If
the scale does not have many items it may be very difﬁcult to
achieve adequate internal consistency. Our ﬁnding is similar to theTable 7
Correlationsa between SF-36 domains and QOLIE-31 domains.
SF-36 domains (n=203) QOLIE-31 domains
Seizure
worry
Overall quality
of life
Emotional
well-being
Energ
Physical functioning 0.202* 0.413* 0.449* 0.470
Role physical 0.127 0.187* 0.279* 0.215
Bodily pain 0.241* 0.396* 0.376* 0.389
General health 0.338* 0.478* 0.478* 0.435
Vitality 0.287* 0.636* 0.715* 0.782
Social functioning 0.308* 0.546* 0.552* 0.560
Role emotional 0.238* 0.469* 0.462* 0.477
Mental health 0.390* 0.724* 0.854* 0.685
a Pearson’s correlation coefﬁcients.
* p<0.05.results of the US,6 Italian19 and Czech studies22 but higher than in
the Spanish16 and Greek studies.20
The test–retest correlation coefﬁcients of theQOLIE-31 Serbian-
language version (0.83 for overall score) was lower than those
reported in US (0.89),6 Spanish (0.90)16 and Greek studies (0.92)20
but similar to the score obtained in the German study (0.80).17
Missing values in our study were frequent only for the items
‘‘driving’’ (27.1%) and ‘‘working limitations’’ (3.4%) from the
Social functioning domain. In the Italian study19 the rate of
missing responses for ‘‘driving’’ (41.9%) and for ‘‘working
limitations’’ (33.4%) was even higher. In the Czech study22 the
responses for ‘‘driving’’ were missing in 33% of the 221 patients.
The majority of patients included in our study did not drive and
many of them were unemployed (25.1%). Therefore, these
ﬁndings probably reﬂect life restrictions caused by epilepsy.
Intercultural differences may also contribute to the differences in
missing responses to the item ‘‘driving’’. It was suggested thatQOLIE overall score
y/Fatigue Cognitive Medication
effects
Social
function
* 0.421* 0.191* 0.442* 0.50*
* 0.223* 0.095 0.211* 0.26*
* 0.374* 0.230* 0.331* 0.44*
* 0.447* 0.351* 0.435* 0.54*
* 0.635* 0.335* 0.518* 0.74*
* 0.484* 0.352* 0.561* 0.63*
* 0.453* 0.269* 0.367* 0.51*
* 0.696* 0.319* 0.534* 0.80*
Zˇ. Martinovic´ et al. / Seizure 19 (2010) 517–524522vital importance of driving as a part of social life may differ in
various cultures.22 The use of public transport (bus or train) to
commute to work or for traveling may be more acceptable in
some countries than in others. Additional comments provided by
patients may serve to overcome the problems caused by missing
values with the items ‘‘driving’’ and ‘‘working’’ in the Social
functioning domain. A further study could investigate whether or
not it would be useful to add ‘‘problems with travelling or
transport’’ to the item ‘‘driving’’22 in order to make it more
comprehensive or informative.
4.2. Validity of the Serbian-language version
The factorial structure of the Serbian-language version of
QOLIE-31 was similar to that of the US version reported by
Cramer et al.,6 as well as of German17 and Czech22 versions. The
ﬁrst factor was heterogeneous, consisting of Emotional well-
being, Overall quality of life and Energy/Fatigue in our, US and
German study; in the Czech study it contained Emotional well-
being and Energy/Fatigue. This factor appears to represent mood
and overall quality of life. However, minor differences exist: in
the study of Cramer et al.,6 Medication effects is one single
factor while in our study it spreads over two factors: two
items load on one factor together with two Social function
items, but the third item is tied to the Seizure worry factor. A
probable explanation is that PWE with good compliance with
antiepileptic drugs such as those included in our study had
relatively low mean overall score on the Neurotoxicity scale-
II26: 12.23  15.24. This value is much lower than the mean score
of 20.6  16.6 in the group of 189 patients with epilepsy in the
study by Aldenkamp and Baker.26 Consequently, we assume that
our patients could not clearly differentiate adverse inﬂuences of
medication on the quality of life from other adverse inﬂuences. On
the other hand, all domains (including Medication effect) showed
high item-scale correlations (r = 0.746–0.911) which is indicative
of good construct validity. Further studies might be necessary in
order to investigate in more detail the relationship between
medication effects and noncompliance on QOL.
Multitrait-scaling analysis showed satisfactory construct
validity of QOLIE-31, since all items showed stronger correla-
tions with scales which they construct than with other scales.
Together with good internal consistency obtained in reliability
analysis, these ﬁndings allow us to conclude that QOLIE-31 has
satisfactory construct validity. Nevertheless, it should be noted
that its structure cannot be conﬁrmed by factor analysis and
that it seems to vary across different versions. One probable
reason might be the speciﬁcity of populations investigated in
different studies.
We further demonstrated good construct validity of the
Serbian-language version of QOLIE-31 by showing that seizure
severity and etiology of epilepsy inﬂuence all domains of QOLIE-31
except the Medication effect scale. The best QOL was reported by
PWE without seizures in the past year and by PWE with an
idiopathic etiology. Inversely, QOL was worst in the subgroup of
PWE with high seizure severity scores and with symptomatic
etiology. The associations between QOLIE-31 and socio-demo-
graphic variables were demonstrated as well. Employment status
was associated with Overall quality of life, Emotional well-being
and Social function scores while education level was associated
with Emotional well-being scores. These results suggest that
QOLIE-31 includes a wide spectrum of concerns facing PWE, as
conﬁrmed in many previous clinical studies.6,16–22,33,34 Further
cross-cultural comparisons between populations with epilepsy
could provide more useful information about the impact of
epilepsy and its’ associations with other factors in various
countries worldwide.All QOLIE-31 dimensions in our study population showed a
high correlation with SF-36 that can be explained by the fact
that these domains contain some practically identical items.
These ﬁndings provide a further strong argument in favor of
good criterion validity of the Serbian-language version of QOLIE-
31 especially since the canonic correlation between the scales is
high (rho = 0.898).35 Likewise, in the study of Beghi et al.,19
comparable correlations were found between QOLIE-31 Overall
QOL and SF-36 General health and Vitality; Energy–Fatigue with
SF-36 Vitality; and Emotional well-being with SF-36 Mental
health.
Lowest correlations of Medications effect and Seizure worry
domains of QOLIE-31 with the general HRQOL questionnaire SF-36
suggest the speciﬁcity of these domains for epilepsy. A weak
relation of these domains of QOLIE-31 with general aspects of
HRQOL is also evident in the study of Beghi et al.19
As expected, QOLIE-31 and NTS-II scores were highly correlated
since they may be both related to the seizures and medications
effects predominantly affecting the central nervous system.
Similarly, Cramer et al. showed high correlations between
neurotoxicity scores and QOLIE-31.6
The assessment of discriminative power of the Serbian
version of QOLIE-31 disclosed that almost all domains were
skewed toward higher scores. This resulted in a somewhat
higher mean overall score in our study (70.67  17.74) than in
the original American version (63  16). This difference is probably
due to the inclusion of 61 (30%) patients with idiopathic epilepsy in
our study (Table 2). Majority (57.4%) of these patients are seizure-
free and in 13.1% of them antiepileptic medication was withdrawn.
Additionally, seizures in the past year were completely controlled
in 37.9% of PWE in present study. A much lower percentage (6.9%)
of PWE without seizures in the past year was reported by
Cramer et al.6
Several shortcomings of our study have to be noted. One of
them is that female subjects predominated; however, the
difference between male and female subjects was not statisti-
cally signiﬁcant. A lower QOL in females than in males was
found in some36,37 but not in all studies.38 Serbian-language
versions of SF-36 and NTS-II have not been psychometrically
evaluated yet so we must be aware of this further limitation
when interpreting these results. Serbian validation of SF-36
would enable to get norms of QOL for healthy population and for
various disease entities and to make meaningful comparison of
QOL between PWE and populations with various disease
entities.39 Also, further studies are needed to examine respon-
siveness of Serbian-language QOLIE-31 to clinical changes,
including efﬁcacy and tolerability of the new antiepileptic
drugs11,14 or epilepsy surgery.16
5. Conclusion
Even with the aforementioned shortcomings, Serbian-language
version of QOLIE-31 shows fairly satisfactory psychometric
properties—good reliability, high internal consistency, and a high
degree of conceptual similarity to the original American version.6
Therefore, Serbian adaptation of QOLIE-31 may be considered as a
reliable and valid questionnaire for further studies of quality of life
in PWE.
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Appendix B (Continued )
Item SW OQL EWB E/F COG ME SF Overall
score
ME2 0.451** 0.291** 0.250** 0.248** 0.370** 0.911** 0.528** 0.486**
ME3 0.408** 0.313** 0.254** 0.264** 0.396** 0.885** 0.564** 0.505**
SW: Seizure worry; OQL: Overall quality of life; EWB: Emotional well-being; E/F:
Energy/Fatigue; COG: Cognitive; ME: Medication effects; SF: Social function.
* p < 0.05.
** p < 0.001.
Zˇ. Martinovic´ et al. / Seizure 19 (2010) 517–524 523Appendix A. Structure matrix, after varimax rotation (only
items with factor loadings greater than 0.5 are shown)
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
EWB3 0.801
E/F1 0.787
EWB5 0.734
E/F2 0.726
OQL2 0.692
OQL1 0.657
EF3 0.538
EWB4 0.534
EWB2 0.513
EWB1 0.502
E/F4 0.511
COG3 0.744
COG2 0.705
COG5 0.677
COG4 0.674
COG6 0.605
SF2 0.508
SW4 0.838
SW2 0.746
SW3 0.722
ME1 0.710
SW5 0.542
SW1 0.527
ME3 0.769
SF4 0.751
SF5 0.743
ME2 0.709
COG1 0.690
SF1 0.647
SF3 0.641
SW: Seizure worry; OQL: Overall quality of life; EWB: Emotional well-being; E/F:
Energy/Fatigue; COG: Cognitive; ME: Medication effects; SF: Social function; OS:
Overall score.Appendix B. Convergent and discriminant validity: correlation
(Pearson’s correlation coefﬁcients) between QOLIE-31 items
and subscales
Item SW OQL EWB E/F COG ME SF Overall
score
OQL1 0.307** 0.886** 0.624** 0.580** 0.546** 0.312** 0.440** 0.682**
E/F1 0.226** 0.624** 0.673** 0.781** 0.513** 0.215** 0.348** 0.628**
EWB1 0.233** 0.527** 0.746** 0.531** 0.534** 0.133 0.293** 0.586**
EWB2 0.313** 0.509** 0.810** 0.635** 0.645** 0.179* 0.431** 0.693**
EWB3 0.251** 0.606** 0.785** 0.661** 0.510** 0.202** 0.351** 0.633**
E/F2 0.223** 0.564** 0.630** 0.827** 0.524** 0.184** 0.415** 0.641**
EWB4 0.285** 0.571** 0.845** 0.658** 0.583** 0.242** 0.481** 0.705**
E/F3 0.204** 0.512** 0.673** 0.833** 0.550** 0.217** 0.421** 0.651**
EWB5 0.339** 0.616** 0.823** 0.621** 0.516** 0.317** 0.432** 0.675**
E/F4 0.243** 0.470** 0.535** 0.802** 0.583** 0.216** 0.406** 0.628**
SW1 0.719** 0.340** 0.379** 0.307** 0.428** 0.312** 0.462** 0.531**
COG1 0.336** 0.464** 0.523** 0.514** 0.643** 0.284** 0.480** 0.637**
SF1 0.461** 0.446** 0.428** 0.364** 0.503** 0.319** 0.678** 0.617**
OQL2 0.373** 0.883** 0.633** 0.602** 0.517** 0.286** 0.445** 0.684**
COG2 0.301** 0.497** 0.584** 0.579** 0.796** 0.314** 0.507** 0.719**
COG3 0.328** 0.587** 0.602** 0.575** 0.838** 0.288** 0.512** 0.752**
COG4 0.389** 0.459** 0.518** 0.521** 0.774** 0.252** 0.438** 0.673**
COG5 0.225** 0.179* 0.345** 0.285** 0.599** 0.122 0.330** 0.454**
SF2 0.444** 0.423** 0.423** 0.441** 0.544** 0.252** 0.660** 0.628**
SF3 0.318** 0.179* 0.154 0.178* 0.243** 0.283** 0.536** 0.352**
SW2 0.834** 0.350** 0.321** 0.226** 0.359** 0.368** 0.436** 0.497**
SW3 0.759** 0.206** 0.153* 0.109 0.301** 0.404** 0.370** 0.384**
SW4 0.843** 0.282** 0.300** 0.186** 0.372** 0.491** 0.428** 0.487**
ME1 0.537** 0.245** 0.199** 0.142* 0.286** 0.746** 0.376** 0.389**
SW5 0.739** 0.324** 0.240** 0.222** 0.347** 0.521** 0.500** 0.487**
COG6 0.470** 0.486** 0.492** 0.500** 0.736** 0.554** 0.609** 0.725**
SF4 0.399** 0.336** 0.356** 0.376** 0.509** 0.522** 0.791** 0.622**
SF5 0.430** 0.390** 0.404** 0.410** 0.504** 0.606** 0.823** 0.658**References
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